| http://www.w3.org/ns/prov#value | - With an administration time of approximately five minutes compared to the approximately 2.5 hour infusion time for intravenous MabThera, this innovative formulation could potentially save time for patients, physicians and other health care providers in Europe.The European approval was primarily based on data from the pivotal SABRINA study, which was recently published in the Lancet Oncology[i].
|
